Once a pharmaceutical product or medical device enters the market, real-world use generates information that may not have been fully visible during clinical development, validation, or premarket evaluation. Patients may have different characteristics, healthcare professionals may use products in broader populations, and devices may be exposed to operating conditions that were difficult to reproduce during development.

Post-Market Surveillance (PMS) is the structured process of collecting, evaluating, and acting on information about the safety, quality, performance, and effectiveness of products after commercialization.

For pharmaceutical companies, post-market surveillance is closely connected to pharmacovigilance and drug safety activities. Organizations may need to evaluate adverse events, medication errors, product quality complaints, scientific literature, safety databases, and other sources of information.

For medical device manufacturers, surveillance can involve complaints, adverse events, malfunctions, service records, literature, registry information, trend data, and feedback from distributors, importers, healthcare professionals, and users.

The FDA explains that postmarketing surveillance is essential because not every potential adverse effect can be identified through preapproval studies. Postmarket information can lead to safety communications, labeling changes, or additional regulatory action when necessary.

This makes PMS more than a reporting exercise. It becomes an ongoing feedback loop between real-world product performance, quality systems, risk management, and regulatory decision-making.

FDA Requirements — 21 CFR Part 803, MDR and FAERS Reporting

For medical devices, 21 CFR Part 803 establishes Medical Device Reporting (MDR) requirements. Manufacturers and importers generally must report certain device-related events when information reasonably suggests that a marketed device may have caused or contributed to a death or serious injury, or when a malfunction could cause or contribute to death or serious injury if it recurred.

Electronic reporting is an important part of modern MDR compliance. FDA requires manufacturers and importers to submit applicable MDRs electronically unless an exemption applies.

For pharmaceutical products, adverse-event reporting is a central component of pharmacovigilance. FDA’s FAERS, now transitioning into the broader FDA Adverse Event Monitoring System (AEMS), supports post-marketing safety surveillance for drugs and therapeutic biologics. The system receives adverse-event, medication-error, and certain product-quality reports and supports the identification of potential safety signals.

An important 2026 development is the continued implementation of AEMS. FDA describes AEMS as a unified system intended to improve data quality, standardization, analytics, and cross-product safety surveillance.

Organizations therefore need safety systems capable of maintaining accurate case information, traceability, standardized data, appropriate reporting workflows, and documented decision-making.

EU MDR Post-Market Surveillance Requirements

Companies operating in Europe must also consider the requirements of the EU Medical Device Regulation (EU MDR).

Under Article 83, manufacturers must plan, establish, document, implement, maintain, and update a post-market surveillance system that is proportionate to the device’s risk class and appropriate to its type. The PMS system should actively and systematically gather, record, and analyze information about device quality, performance, and safety throughout the product’s lifetime.

EU MDR PMS activities can include information from:

• Serious incidents and field safety corrective actions
• Non-serious incidents and undesirable side effects
• Trend reporting
• Scientific and technical literature
• Databases and registers
• User, distributor, and importer feedback
• Complaints and market experience
• Information concerning similar medical devices

The regulation also connects PMS activities with preventive and corrective actions and ongoing benefit-risk evaluation. This means PMS cannot operate as an isolated regulatory department. It needs to connect with quality management, risk management, clinical evaluation, complaint handling, vigilance, and corrective action processes.

How to Build a PMS Plan That Satisfies FDA and EMA

A strong PMS plan begins with clearly defined objectives and responsibilities.

Organizations should first identify the products, markets, risk profiles, applicable regulations, and data sources covered by the surveillance program. The plan should explain how information will be collected, evaluated, documented, escalated, and reported.

A practical PMS framework should include:

1. Defined data sources:
   Establish procedures for collecting complaints, adverse events, literature information, clinical data, customer feedback, distributor information, service records, and other relevant evidence.
2. Clear escalation criteria:
   Not every complaint represents the same level of risk. Define criteria for determining when an event requires investigation, regulatory reporting, CAPA, safety review, or management escalation.
3. Documented evaluation procedures:
   Safety information should be assessed consistently using controlled procedures and qualified personnel.
4. Regulatory reporting workflows:
   Reporting responsibilities, timelines, review processes, approvals, and submission records should be clearly documented.
5. Periodic safety evaluation:
   Organizations should continuously evaluate whether accumulated information changes the product’s safety or benefit-risk profile.
6. CAPA integration:
   When surveillance identifies a recurring issue, the organization should be able to connect the finding with investigation, root-cause analysis, corrective action, preventive action, and effectiveness monitoring.

For pharmaceutical companies, the system should integrate pharmacovigilance processes with applicable safety reporting and periodic benefit-risk activities. For medical device organizations, PMS should remain connected with complaint handling, vigilance, risk management, clinical evaluation, and quality management.

BioNetwork Consulting can support organizations with regulatory compliance, CSV, quality, clinical operations, and life sciences consulting capabilities, helping companies develop practical frameworks that align technology and operational processes with regulatory expectations.

Signal Detection and Benefit-Risk Evaluation

Collecting safety information is only the beginning. The real value of PMS comes from identifying meaningful patterns.

Signal detection involves reviewing safety data to identify potential new risks or changes in known risks. Signals may emerge from individual case reports, clusters of similar events, complaint trends, scientific publications, clinical information, or other sources.

A robust Pharmacovigilance & Drug Safety Systems program should establish documented methods for:

• Identifying potential safety signals
• Prioritizing signals according to risk
• Reviewing supporting evidence
• Assessing causality and clinical relevance
• Determining whether additional investigation is required
• Documenting conclusions
• Escalating significant findings
• Evaluating potential regulatory or labeling implications

Benefit-risk evaluation is equally important. A safety finding should not automatically be viewed in isolation. Organizations must consider the severity and frequency of the risk alongside the product’s therapeutic or clinical benefits, available alternatives, patient population, and relevant evidence.

This ongoing assessment allows companies to make informed decisions while demonstrating that safety information is being actively monitored and appropriately managed.

Common PMS Failures That Lead to FDA Enforcement

Many compliance problems are not caused by a complete absence of a surveillance program. They occur because the program is fragmented, poorly documented, or disconnected from operational systems.

Common weaknesses include:

Incomplete Complaint Handling

Complaints may be recorded without adequate investigation, classification, escalation, or linkage to adverse-event reporting.

Missed Reporting Timelines

Delays can occur when organizations lack clearly assigned responsibilities or automated workflows for determining whether an event is reportable.

Poor Data Quality

Incomplete case information, inconsistent terminology, duplicate records, or weak data governance can affect safety assessment and regulatory reporting.

Weak Signal Detection

Organizations may collect large volumes of safety information but lack the analytical processes necessary to identify meaningful trends.

Disconnected Quality and Safety Systems

When pharmacovigilance, complaint handling, CAPA, quality, and risk management systems operate independently, important information can be missed.

Insufficient Documentation

During an inspection, regulators need to understand not only what decision was made but also why it was made. Organizations should maintain evidence of assessments, reviews, escalations, reports, approvals, and follow-up activities.

Limited Inspection Readiness

Inspection readiness should not begin when an FDA investigator arrives. Procedures, training, records, electronic systems, validation documentation, and safety processes should remain inspection-ready as part of normal operations.

BioNetwork Consulting’s experience in Computer System Validation (CSV), GxP compliance, clinical operations, and regulatory consulting can help organizations strengthen the systems and processes supporting these activities.

Why FDA Inspection Readiness Should Start Before an Inspection

FDA inspection readiness is fundamentally about maintaining continuous control.

Companies should periodically assess whether their PMS and pharmacovigilance processes can demonstrate:

• Accurate and complete safety records
• Controlled procedures and work instructions
• Appropriate employee training
• Validated or appropriately controlled computerized systems
• Traceable safety decisions
• Timely regulatory reporting
• Effective complaint and CAPA processes
• Documented signal evaluation
• Consistent risk management
• Clear management oversight

For medical device organizations, FDA’s postmarket requirements can include MDR compliance and, for applicable devices, postmarket surveillance activities under Section 522. FDA describes Section 522 surveillance as active, systematic, scientifically valid collection, analysis, and interpretation of information about marketed devices.

Being prepared means having the evidence available to demonstrate that these processes operate effectively—not simply having policies stored in a document management system.

How BioNetwork Consulting Supports Life Sciences Organizations

BioNetwork Consulting helps pharmaceutical, biotechnology, and medical device organizations navigate the intersection of compliance, technology, clinical operations, and specialized talent.

Its expertise includes Computer System Validation for GxP-regulated systems, quality and regulatory support, clinical trial recruitment, and life sciences consulting.

For organizations strengthening Post-Market Surveillance & Vigilance Support, Pharmacovigilance & Drug Safety Systems, or FDA Inspection Readiness, an integrated approach can help connect regulatory requirements with the people, processes, and technology required to execute them effectively.

The goal is not simply to respond to regulatory requirements after a problem occurs. It is to establish sustainable systems that continuously capture information, identify risks, support informed decisions, and protect product quality and patient safety.

FAQ: Post-Market Surveillance, Pharmacovigilance and FDA Readiness

1. What is post-market surveillance?

Post-market surveillance is the systematic collection and evaluation of information about a marketed product’s safety, quality, performance, and effectiveness. It helps organizations identify emerging risks and determine whether corrective or preventive actions are necessary.

2. What is the difference between PMS and pharmacovigilance?

PMS is a broader post-market framework, particularly prominent in medical device regulation, while pharmacovigilance focuses primarily on detecting, assessing, understanding, and preventing adverse effects and other medicine-related safety problems.

3. What does 21 CFR Part 803 cover?

21 CFR Part 803 establishes FDA’s Medical Device Reporting requirements for certain device-related adverse events and malfunctions. Manufacturers and importers have specific reporting obligations when applicable conditions are met.

4. Is FAERS still relevant in 2026?

Yes. FDA’s historical FAERS database remains an important reference for post-marketing drug safety surveillance, while FDA is implementing AEMS as its broader Adverse Event Monitoring System.

5. What is FDA inspection readiness?

FDA inspection readiness means maintaining the processes, systems, records, training, documentation, and evidence necessary to demonstrate ongoing regulatory compliance. It should be treated as a continuous operational practice rather than a last-minute preparation exercise.

6. Why is signal detection important?

Signal detection helps organizations identify potential safety concerns or changes in known risks by analyzing information collected from adverse-event reports, complaints, literature, clinical data, and other sources.

7. Can BioNetwork Consulting support pharmacovigilance and regulatory readiness?

BioNetwork Consulting provides life sciences consulting focused on regulatory compliance, CSV, clinical operations, and specialized talent. Its integrated approach can help organizations strengthen the people, systems, and processes supporting regulated operations.

Moving Toward Continuous Safety and Compliance

Post-market surveillance is becoming increasingly important as pharmaceutical and medical device organizations manage larger volumes of real-world data and increasingly complex regulatory expectations. Companies need more than individual reporting processes—they need connected systems that bring together safety information, quality, technology, clinical expertise, regulatory knowledge, and qualified personnel.

With the right PMS strategy, organizations can identify safety signals earlier, maintain stronger documentation, improve benefit-risk decision-making, and remain better prepared for regulatory scrutiny.

BioNetwork Consulting brings together regulatory expertise, Computer System Validation, clinical recruitment, and life sciences consulting to help organizations build that foundation. By connecting compliance and talent, companies can move toward a more proactive model of regulatory readiness while supporting safer, higher-quality products throughout their lifecycle.

For pharmaceutical, biotechnology, and medical device organizations preparing for the next stage of growth, strong post-market surveillance is not simply a compliance requirement. It is an essential part of responsible innovation.